Hantz Financial Services’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$258K Buy
5,072
+1,669
+49% +$77.9K ﹤0.01% 902
2025
Q4
$100K Buy
3,403
+691
+25% +$18.8K ﹤0.01% 1145
2025
Q3
$70K Buy
2,712
+1,985
+273% +$55.4K ﹤0.01% 1108
2025
Q2
$20K Buy
727
+630
+649% +$16.6K ﹤0.01% 1276
2025
Q1
$3K Sell
97
-13
-12% -$461 ﹤0.01% 1301
2024
Q4
$5K Sell
110
-45
-29% -$2.15K ﹤0.01% 893
2024
Q3
$10K Buy
155
+2
+1% +$184 ﹤0.01% 791
2024
Q2
$18K Sell
153
-118
-44% -$14.9K ﹤0.01% 738
2024
Q1
$29K Sell
271
-170
-39% -$17.1K ﹤0.01% 711
2023
Q4
$44K Buy
441
+2
+0.5% +$168 ﹤0.01% 662
2023
Q3
$45K Buy
439
+19
+5% +$2.12K ﹤0.01% 641
2023
Q2
$51K Hold
420
﹤0.01% 623
2023
Q1
$65K Buy
420
+1
+0.2% +$165 ﹤0.01% 599
2022
Q4
$75K Buy
419
+127
+43% +$20.8K ﹤0.01% 587
2022
Q3
$35K Hold
292
﹤0.01% 621
2022
Q2
$42K Hold
292
﹤0.01% 603
2022
Q1
$50K Buy
+292
New +$49.2K ﹤0.01% 612
2021
Q1
Sell
-801
Closed -$84K 721
2020
Q4
$84K Buy
801
+733
+1,078% +$74.2K ﹤0.01% 472
2020
Q3
$5K Sell
68
-35
-34% -$2.44K ﹤0.01% 519
2020
Q2
$7K Buy
+103
New +$5.64K ﹤0.01% 492

Other funds holding MRNA

Hantz Financial Services's MRNA Position: Q1 2026 in Review

Hantz Financial Services increased its Moderna (MRNA) stake by 49% in Q1 2026, buying an estimated $77.9K and bringing the position to 5,072 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #902.

Hantz Financial Services first reported a position in MRNA in Q2 2020 and has held it in 20 quarters since. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Hantz Financial Services held 5,072 shares of Moderna worth $258K as of Q1 2026.
  • Hantz Financial Services bought 1,669 Moderna shares in Q1 2026, an estimated $77.9K.
  • Moderna made up ﹤0.01% of Hantz Financial Services's portfolio in Q1 2026, its #902 holding.
  • Hantz Financial Services first reported a position in Moderna in Q2 2020 and has held it in 20 quarters since.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Hantz Financial Services's 13F filing for Q1 2026, filed 1 May 2026.